(Insulin human + pramlintide) is under clinical development by Xeris Biopharma and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Insulin human + pramlintide)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Insulin human + pramlintide) overview

Insulin in fixed dose combination with pramlintide is under development for the treatment of type 1 and type 2 diabetes. It is administered through subcutaneous route. Pramlintide is a synthetic analog of human amylin, a naturally occurring neuroendocrine hormone synthesized by pancreatic beta cells which acts by targeting islet amyloid polypeptide and insulin acts by targeting insulin receptor. It is developed based on XeriSol technology.

Xeris Biopharma overview

Xeris Biopharma (XERIS) is the specialty pharmaceutical company that develops novel technology platforms to develop and commercialize stable injectable and infusible drug formulations. The company’s XeriSol formulation technology enables the subcutaneous and intramuscular delivery of concentrated formulations of proteins, peptides, antibodies and small molecules using syringes, multi-dose pens, auto-injectors and pumps. XERIS’s products are used in therapeutic areas such as severe hypoglycemia, post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure, exercise-induced hypoglycemia, acute repetitive seizures and type 1/type 2 blood sugar controls. It caters to caregivers, health practitioners and patients. XERIS is headquartered in Chicago, Illinois, the US.

For a complete picture of (Insulin human + pramlintide)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.